Morgan’s US office probs behind their ANP interest / coverage here imo.
Take a look at valuations of these 3 NASDAQ companies in the DMD space. Only a Sarepta has FDA approved drug.
Sarepta US$6.8B
Solid Bioscience US$522m
Wave Life Sciences US$923m
With 3 x positive Phase 2 read outs, ANP’s poultry $40m market cap has a LOT of catching up to do.
.
Media coverage, page-9
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $177.5K | 1.730M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 136159 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 233891 | 3 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |